FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packageus.nlm.vsac
Resource TypeValueSet
IdValueSet-2.16.840.1.113762.1.4.1116.602.json
FHIR VersionR4
Sourcehttps://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1116.602/expansion
URLhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.602
Version20240703
Statusactive
Date2024-07-03T01:06:58-04:00
NameNeurokinin1ReceptorAntagonist
TitleNeurokinin 1 Receptor Antagonist
Realmus
Authorityhl7
Purpose(Clinical Focus: The purpose of this value set is to represent concepts of medication for Neurokinin 1 Receptor Antagonist.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for Neurokinin 1 Receptor Antagonist: rolapitant, aprepitant, fosnetupitant palonosetron, netupitant palonosetron, fosaprepitant),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)

Resources that use this resource

No resources found


Resources that this resource uses

CodeSystem
rxnormRxNorm
ValueSet
2.16.840.1.113762.1.4.1116.222Aprepitant Oral
2.16.840.1.113762.1.4.1116.223Fosaprepitant Injectable
2.16.840.1.113762.1.4.1116.560Rolapitant Oral
2.16.840.1.113883.3.1444.3.144Netupitant Palonosetron Oral
2.16.840.1.113883.3.1444.3.145Fosnetupitant Palonosetron Injectable
2.16.840.1.113883.3.1444.3.146Aprepitant Injectable
2.16.840.1.113883.3.1444.3.147Rolapitant Injectable

Narrative

No narrative content found in resource


Source1

{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.602",
  "meta": {
    "versionId": "17",
    "lastUpdated": "2024-07-03T01:06:58.000-04:00",
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail": {
        "name": "American Society of Clinical Oncology Author"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate": "2025-04-08"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate": "2024-07-03"
    }
  ],
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.602",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113762.1.4.1116.602"
    }
  ],
  "version": "20240703",
  "name": "Neurokinin1ReceptorAntagonist",
  "title": "Neurokinin 1 Receptor Antagonist",
  "status": "active",
  "date": "2024-07-03T01:06:58-04:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "US"
        }
      ]
    }
  ],
  "purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medication for Neurokinin 1 Receptor Antagonist.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for Neurokinin 1 Receptor Antagonist: rolapitant, aprepitant, fosnetupitant palonosetron, netupitant palonosetron, fosaprepitant),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
  "compose": {
    "include": [
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.145"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.147"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.144"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.146"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.223"
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:960fc6bc-3e91-449f-8b3e-d9be3a36f4a2",
    "timestamp": "2025-05-23T18:19:31-04:00",
    "total": 15,
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1552343",
        "display": "netupitant 300 MG / palonosetron 0.5 MG Oral Capsule"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1665503",
        "display": "rolapitant 90 MG Oral Tablet"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1729308",
        "display": "aprepitant 125 MG Powder for Oral Suspension"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1731075",
        "display": "fosaprepitant 115 MG Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1731077",
        "display": "fosaprepitant 150 MG Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1986885",
        "display": "92.5 ML rolapitant 1.8 MG/ML Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "1995150",
        "display": "18 ML aprepitant 7.2 MG/ML Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "2044429",
        "display": "fosnetupitant 235 MG / palonosetron 0.25 MG Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "2374366",
        "display": "20 ML fosnetupitant 11.75 MG/ML / palonosetron 0.0125 MG/ML Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "2631783",
        "display": "4.4 ML aprepitant 7.2 MG/ML Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "2664065",
        "display": "50 ML fosaprepitant 3 MG/ML Injection"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "403810",
        "display": "aprepitant 80 MG Oral Capsule"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "403811",
        "display": "aprepitant 125 MG Oral Capsule"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "644088",
        "display": "aprepitant 40 MG Oral Capsule"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05052025",
        "code": "754508",
        "display": "{1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack"
      }
    ]
  }
}